Audentes Therapeutics, Inc.
They are a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.
Last Closing Price
January 25, 2018
BofA Merrill Lynch, Cowen & Co., Leerink
To view the prospectus for Audentes Therapeutics, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277